Management of patients with post-transplant lymphoproliferative disorder: the role of rituximab
Authors:
- 1 April 2006
- journal article
- review article
- Published by Frontiers Media SA in Transplant International
- Vol. 19 (4) , 259-269
Abstract
Post-transplant lymphoproliferative disorder (PTLD) is a serious complication of solid organ and bone marrow transplantations. Rituximab (Rituxan, Mabthera), a chimeric monoclonal antibody to the CD20 antigen on the surface of B-cell lymphocytes, has been used increasingly in the treatment of PTLD. Rituximab was initially approved for the treatment of low-grade non-Hodgkin lymphomas, but multiple case studies, retrospective analyses, and phase II trials demonstrate the benefit of rituximab in PTLD. This paper reviews the current data on rituximab and its promising role in the management of PTLD.Keywords
This publication has 92 references indexed in Scilit:
- Long-Term Results of the R-CHOP Study in the Treatment of Elderly Patients With Diffuse Large B-Cell Lymphoma: A Study by the Groupe d'Etude des Lymphomes de l'AdulteJournal of Clinical Oncology, 2005
- A single amino acid change, A91V, leads to conformational changes that can impair processing to the active form of perforinBlood, 2005
- Rituximab Therapy for Patients With Newly Diagnosed, Advanced-Stage, Follicular Grade I Non-Hodgkin's Lymphoma: A Phase II Trial in the North Central Cancer Treatment GroupJournal of Clinical Oncology, 2005
- B cell depletion as a novel treatment for systemic lupus erythematosus: A phase I/II dose‐escalation trial of rituximabArthritis & Rheumatism, 2004
- Management of Immune Thrombocytopenic Purpura in AdultsMayo Clinic Proceedings, 2004
- Successful treatment of refractory myasthenia gravis using rituximab: a pediatric case reportThe Journal of Pediatrics, 2003
- Epstein–Barr virus post‐transplant lymphoproliferative disease and virus‐specific therapy: pharmacological re‐activation of viral target genes with arginine butyrateTransplant Infectious Disease, 2001
- Treatment of post-transplant lymphoproliferative disease with induction chemotherapy followed by haploidentical peripheral blood stem cell transplantation and RituximabBone Marrow Transplantation, 2001
- CD20: a regulator of cell-cycle progression of B lymphocytesImmunology Today, 1994
- Anti–B-Cell Monoclonal Antibodies in the Treatment of Severe B-Cell Lymphoproliferative Syndrome Following Bone Marrow and Organ TransplantationNew England Journal of Medicine, 1991